Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pharmacokinetics and safety Profiles after administration of DA-5218 and co-administration of DA-5218-R1, DA-5218-R2 and DA-5218-R3 in healthy adult volunteers
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A | Experimental |
| |
| Sequence B | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DA-5218 | Drug | single dose administration (DA-5218 one tablet once a day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUCt | area under the curve | pre-dose~72 hours post-dose |
| Cmax | maximum plasma concentration | pre-dose~72 hours post-dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| JiHyun Sung | Contact | +82-2-920-8369 | jhsung@donga.co.kr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bumin Hospital | Seoul | 07590 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DA-5218-R1 + DA-5218-R2 + DA-5218-R3 | Drug | single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day) |
|